https://medicalxpress.com/news/2024-03-fda-car-cell-therapy-adults.html
Another CAR-T approval. First therapy for adults with leukemia or lymphoma, another bar set.
Accelerated approval was based on response rate and duration of response.
"The results of the phase 1/2 trial of 89 patients indicated a complete response rate of 20 percent with Breyanzi treatment"
"The overall response rate was 45 percent, with a median duration of response of 35.3 months. Across patients treated with Breyanzi who achieved a complete response, the minimal residual disease negativity rate was 100 percent in the blood and 92.3 percent in the bone marrow"
- Forums
- ASX - By Stock
- Ann: Clinical milestones for 2024 & 2023 successes highlighted
https://medicalxpress.com/news/2024-03-fda-car-cell-therapy-adult...
-
- There are more pages in this discussion • 10 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add CHM (ASX) to my watchlist
(20min delay)
|
|||||
Last
1.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $12.67M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
CHM (ASX) Chart |
Day chart unavailable